Prenetics Global Ltd. is a genomics-driven health sciences company, which engages in the prevention, early detection, and treatment of diseases. Its prevention arm, CircleDNA, uses whole exome sequencing to offer the comprehensive consumer DNA test for early colorectal cancer screening and saving lives through pioneering multi-cancer early detection technologies. The company's ACT Genomics unit, which is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Prenetics Global was founded by Sheng Wu Yeung and Chi Hung Tzang in 2014 and is headquartered in Hong Kong.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company